Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Codrituzumab |
Synonyms | |
Therapy Description |
Codrituzumab (GC-33) is a monoclonal antibody against Glypican-3 (GPC3), which may result in cytotoxicity due to its association with CD16-Fc-gamma RIIIa (PMID: 27085251, PMID: 31510063). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Codrituzumab | GC-33|RG 7686|RG7686|RG-7686|RO 5137382|RO5137382 | GPC3 Antibody 5 | Codrituzumab (GC-33) is a monoclonal antibody against Glypican-3 (GPC3), which may result in cytotoxicity due to its association with CD16-Fc-gamma RIIIa (PMID: 27085251, PMID: 31510063). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04928677 | Phase I | Codrituzumab | A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment | Recruiting | USA | 0 |